- For the quarter, the company reported revenues of $1.06 billion, up 8.9% from $973.1 million recorded in the prior-year quarter
- Net income attributable to common shareholders was $97.0 million in Q2, compared to $109.3 million for the same period in 2022
- On a per-share basis, Q2 unadjusted earnings decreased 11.3% year-over-year to $1.89 from $2.13 last year
- Adjusted profit was $138.3 million in the June quarter, which is down 2.5% from the prior-year period
- Earnings per share, on an adjusted basis, decreased 2.9% year-over-year to $2.69 during the three-month period
- The management expects revenues to increase in the range of 2.5% to 4.5% in fiscal 2023
Market News
Earnings Summary: Charles River Laboratories reports Q2 2023 results
Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the second quarter of 2023. For the quarter, the company reported revenues of $1.06 billion, up 8.9% from $973.1 million recorded in the prior-year quarter Net income attributable to common shareholders was $97.0 million in Q2, compared to $109.3 million […]
“Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the second quarter of 2023. For the quarter, the company reported revenues of $1.06 billion, up 8.9% from $973.1 million recorded in the prior-year quarter Net income attributable to common shareholders was $97.0 million in Q2, compared to $109.3 million […]
· August 9, 2023
Pharma company Charles River Laboratories International, Inc. (NYSE: CRL) on Wednesday reported financial results for the second quarter of 2023.
ADVERTISEMENT